Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer Aggressiveness
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Trial Timeline
Oct 3, 2017 → Jun 30, 2026
NCT ID
NCT03263650About Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib
Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib is a phase 2 stage product being developed by AstraZeneca for Prostate Cancer Aggressiveness. The current trial status is active. This product is registered under clinical trial identifier NCT03263650. Target conditions include Prostate Cancer Aggressiveness, Prostate Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer Aggressiveness were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03263650 | Phase 2 | Active |
Competing Products
20 competing products in Prostate Cancer Aggressiveness